Designing molecular diagnostics for current tuberculosis drug regimens.
Sophia B Georghiou, Margaretha de Vos, Kavindhran Velen...
https://pubmed.ncbi.nlm.nih.gov/36752055/Actively Recruiting
Led by Foundation for Innovative New Diagnostics, Switzerland · Updated on 2026-09-23
2350
Participants Needed
5
Research Sites
N/A
Total Duration
Researchers are evaluating the diagnostic accuracy and operational features of the Bioneer Accupower Q-RFIA PCR kit used on the IRON qPCR system for detecting tuberculosis TB and resistance to key anti-TB drugs including isoniazid, rifampicin, fluoroquinolones, and aminoglycosides. This multicenter observational study aims to support global and national decisions by providing robust evidence on the validity of this rapid test, which integrates sample preparation and can deliver results within 30 minutes. The study compares the investigational assay with existing diagnostic tests and uses culture and molecular sequencing as reference standards. Participants suspected of pulmonary TB will provide sputum samples that will be tested with the Bioneer RFIA kit and comparator assays such as Xpert MTBRIF Ultra and Xpert MTBXDR. The study assesses both direct sputum samples and cultured isolates to compare diagnostic performance and resolve any discordant results. Additional tests include smear microscopy, culture on different media, phenotypic drug susceptibility testing, and whole genome sequencing for samples with discrepant resistance results. Retrospective specimens from biobanks may also be included for testing. During the study, participants provide sputum specimens which undergo multiple diagnostic tests at various laboratories following standardized procedures. Data on test results and resistance detection are recorded systematically. The primary outcomes include diagnostic accuracy for TB detection and drug resistance identification over 8 months. The study follows rigorous quality control, safety, and ethical standards to ensure reliable results and participant safety throughout the study period ending in mid-2027.
CONDITIONS
Bioneer Q-RFIA Clinical Evaluation
V
Vinzeigh Leukes, PhD
A
Andres De la Rossa, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Foundation for Innovative New Diagnostics, Switzerland
Lead Sponsor
V. N. Karazin Kharkiv National University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 months
Participants provide sputum samples which are tested with the Bioneer RFIA kit and comparator assays to detect tuberculosis and drug resistance.
Sample collection and laboratory testing as scheduled
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Sophia B Georghiou, Margaretha de Vos, Kavindhran Velen...
https://pubmed.ncbi.nlm.nih.gov/36752055/Foundation for Innovative New Diagnostics, Switzerland
Lead Sponsor
V. N. Karazin Kharkiv National University
Collaborating Sponsor